Constellation Bra (STZ) Offering Possible 31.58% Return Over the Next 10 Calendar Days

Constellation Bra's most recent trend suggests a bullish bias. One trading opportunity on Constellation Bra is a Bull Put Spread using a strike $207.50 short put and a strike $202.50 long put offers a potential 31.58% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $207.50 by expiration. The full premium credit of $1.20 would be kept by the premium seller. The risk of $3.80 would be incurred if the stock dropped below the $202.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Constellation Bra is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Constellation Bra is bullish.

The RSI indicator is at 63.95 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Constellation Bra

3 Reasons Big Tobacco and Marijuana Partnerships Are Imminent
Sat, 08 Sep 2018 15:41:00 +0000
With tobacco usage declining, partnering with the pot industry is a logical evolution.

Marijuana ETF in Canada passes $1 billion in assets as weed stocks light it up
Fri, 07 Sep 2018 18:21:00 +0000
The Canadian-listed marijuana ETF, Horizons Marijuana Life Sciences Index ETF (HMMJ), has passed the $1 billion mark in assets. Marijuana ETFs have soared in the past month since liquor giant Constellation Brands announced a $4 billion investment in marijuana stock Canopy Growth. The U.S.-listed ETFMG Alternative Harvest ETF (MJ) was the best-performing ETF in August and is near-$500 million in assets.

Cronos Group Stock Is Your Classic High-Risk, High-Reward Play
Fri, 07 Sep 2018 15:16:50 +0000
Cronos Group (NASDAQ:CRON) had a remarkable week in the markets, which should surprise no one. As a marijuana-related investment, CRON stock is liable to make insane moves. On Wednesday, CRON stock closed up almost 12% above the prior day’s session when management announced a landmark deal with custom-microbe producer Ginkgo Bioworks.

Your first trade for Friday, Sept 7
Fri, 07 Sep 2018 13:30:00 +0000
The ” Fast Money ” traders shared their first moves for the market open. Tim Seymour was a buyer of Constellation Brands STZ David Seaburg was a buyer of Pfizer PFE Dan Nathan was a seller of Taiwan Semiconductor 2330-TW Guy Adami was a buyer of CBS Corp CBS Trader disclosure: On September 6, 2018 the following stocks and commodities mentioned or intended to be mentioned on CNBC's “Fast Money” were owned by the “Fast Money” traders: Tim Seymour is long AMZA, ACB.

New Formats Canopy Growth Plans to Introduce
Fri, 07 Sep 2018 13:01:12 +0000
Cannabis companies plan to offer several products across various formats to access a share in several user experiences. For example, in its announcement related to 100 SKUs (stock keeping units), Canopy Growth (WEED) (CGC) said that its line of cannabis products will include multiple formats such as dried flower, pre-rolled joints, softgel capsules, and oils. Dried flower and pre-rolled joints have traditionally been the preferred format for consuming cannabis.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.